| Literature DB >> 22683611 |
Karen Stanger1, Micah Steffek, Lijuan Zhou, Christine D Pozniak, Clifford Quan, Yvonne Franke, Jeff Tom, Christine Tam, Irina Krylova, J Michael Elliott, Joseph W Lewcock, Yingnan Zhang, Jeremy Murray, Rami N Hannoush.
Abstract
The caspases are a family of cytosolic proteases with essential roles in inflammation and apoptosis. Drug discovery efforts have focused on developing molecules directed against the active sites of caspases, but this approach has proved challenging and has not yielded any approved therapeutics. Here we describe a new strategy for generating inhibitors of caspase-6, a potential therapeutic target in neurodegenerative disorders, by screening against its zymogen form. Using phage display to discover molecules that bind the zymogen, we report the identification of a peptide that specifically impairs the function of caspase-6 in vitro and in neuronal cells. Remarkably, the peptide binds at a tetramerization interface that is uniquely present in zymogen caspase-6, rather than binding into the active site, and acts via a new allosteric mechanism that promotes caspase tetramerization. Our data illustrate that screening against the zymogen holds promise as an approach for targeting caspases in drug discovery.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22683611 DOI: 10.1038/nchembio.967
Source DB: PubMed Journal: Nat Chem Biol ISSN: 1552-4450 Impact factor: 15.040